Detalhe da pesquisa
1.
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Cardiovasc Diabetol
; 21(1): 194, 2022 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36151557
2.
Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients.
Nephrol Dial Transplant
; 37(7): 1375-1383, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35092430
3.
Precision medicine approaches for diabetic kidney disease: opportunities and challenges.
Nephrol Dial Transplant
; 36(Suppl 2): 3-9, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34153985
4.
Comparison of nurses and general caregivers' knowledge, attitude, and practice on medication administration process and their distress level in long-term care facilities across Penang, Kuala Lumpur, and Selangor of Malaysia.
Aging Clin Exp Res
; 30(2): 183-191, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28527134
5.
Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges.
Nephrol Dial Transplant
; 37(6): 1198, 2022 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137912
6.
Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis.
Commun Med (Lond)
; 4(1): 11, 2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38253823
7.
Precision Prognostics for Cardiovascular Disease in Type 2 Diabetes: A Systematic Review and Meta-analysis.
medRxiv
; 2023 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37162891
8.
Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.
Front Pharmacol
; 13: 786767, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35496307
9.
A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores.
Ther Adv Endocrinol Metab
; 12: 2042018820974191, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33613960
10.
Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.
Front Pharmacol
; 12: 786706, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35145402